The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Defining the clinical course of multiple sclerosis: The 2013 revisions
Open accessAbstract
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PPMS (10-15% of patients) is characterised by an insidious, slowly progressive increase in neurological disability over time, usually without relapses.2”
From Diagnosis of multiple sclerosis: progress and challenges (2017) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“At this time it is considered essential that a diagnosis of MS only be made in a patient who has symptoms suggestive of demyelination. 2”
From Diagnosis of multiple sclerosis: progress and challenges (2017) · cites this paper as [2]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Misdiagnosis of MS remains an issue in clinical practice. 8-11”
From Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (2018) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Self-citationDefining the clinical course of multiple sclerosis
LUBLIN, F. D., & Reingold, S. C. (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,762
Self-citationB-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Self-citationJacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,485
The Immunopathology of Multiple Sclerosis: An Overview
Lassmann, H., Brück, W., & Lucchinetti, C. F. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00064.x · Cited by 1,182
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, Ó., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,042
Self-citationProgressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Natural history of multiple sclerosis: a unifying concept
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awl007 · Cited by 901
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H., Miller, D., Montalbán, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237641.33768.8d · Cited by 677
Self-citationIncidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome
Okuda, D. T., Mowry, E. M., Beheshtian, A., Waubant, E., Baranzini, S. E., Goodin, D. S., Hauser, S. L., & Pelletier, D. (2009) · Neurology · doi:10.1212/01.wnl.0000335764.14513.1a · Cited by 642
Self-citation
Cited by
Sorted by citations
Items 201–300 of 1,007
Neurological updates: neurological complications of CAR-T therapy
Tallantyre, E. C., Evans, N. A., Parry-Jones, J., Morgan, M. P. G., Jones, C. H., & Ingram, W. A. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10237-3 · Cited by 100
Cagol, A., Benkert, P., Melie‐García, L., Schaedelin, S. A., Leber, S., Tsagkas, C., Baraković, M., Galbusera, R., Lu, P., Weigel, M., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207768 · Cited by 102
Self-citationManaging the side effects of multiple sclerosis therapy: pharmacotherapy options for patients
Rommer, P. S., & Zettl, U. K. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1446944 · Cited by 99
Molhemi, F., Monjezi, S., Mehravar, M., Yazdi, M. J. S., Salehi, R., Hesam, S., & Mohammadianinejad, S. E. (2020) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2020.09.395 · Cited by 106
Levi, I., Gurevich, M., Perlman, G., Magalashvili, D., Menascu, S., Bar, N., Godneva, A., Zahavi, L., Chermon, D., Kosower, N., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100246 · Cited by 99
Riccio, P., Rossano, R., Larocca, M., Trotta, V., Mennella, I., Vitaglione, P., Ettorre, M., Graverini, A., Santis, A. D., Monte, E. D., et al. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370215618462 · Cited by 97
Peyro‐Saint‐Paul, L., Debruyne, D., Bernard, D., Mock, D. M., & Defer, G. L. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1136288 · Cited by 96
Ciccarelli, O., Barkhof, F., Calabrese, M., Stefano, N. D., Eshaghi, A., Filippi, M., Gasperini, C., Granziera, C., Kappos, L., Rocca, M. A., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209444 · Cited by 96
Self-citationHenry, A., Tourbah, A., Camus, G., Deschamps, R., Mailhan, L., Castex, C., Gout, O., & Montreuil, M. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.09.039 · Cited by 95
Kocevar, G., Stamile, C., Hannoun, S., Cotton, F., Vukusic, S., Durand‐Dubief, F., & Sappey‐Marinier, D. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00478 · Cited by 101
Functional Connectivity in Multiple Sclerosis: Recent Findings and Future Directions
Tahedl, M., Levine, S. M., Greenlee, M. W., Weissert, R., & Schwarzbach, J. V. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00828 · Cited by 99
Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis
Schlaeger, R., Papinutto, N., Zhu, A. H., Lobach, I. V., Bevan, C. J., Bucci, M., Castellano, A., Gelfand, J. M., Graves, J., Green, A., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0993 · Cited by 95
Self-citationProgressive multiple sclerosis
Ontaneda, D., & Fox, R. J. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000195 · Cited by 95
Self-citationCarotenuto, A., Arcara, G., Orefice, G., Cerillo, I., Giannino, V., Rasulo, M., Iodice, R., & Bambini, V. (2017) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acx061 · Cited by 94
Combined therapies to treat complex diseases: The role of the gut microbiota in multiple sclerosis
Calvo‐Barreiro, L., Eixarch, H., Montalbán, X., & Espejo, C. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.11.019 · Cited by 95
Retinal imaging with optical coherence tomography: a biomarker in multiple sclerosis?
Costello, F., & Burton, J. (2018) · Eye and Brain · doi:10.2147/eb.s139417 · Cited by 96
Claes, N., Fraussen, J., Stinissen, P., Hupperts, R., & Somers, V. A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00642 · Cited by 96
Progressive multiple sclerosis, cognitive function, and quality of life
Chow, H. H., Schreiber, K. I., Magyari, M., Ammitzbøll, C., Börnsen, L. S., Christensen, J. R., Ratzer, R. L., Sørensen, P. S., & Sellebjerg, F. T. (2018) · Brain and Behavior · doi:10.1002/brb3.875 · Cited by 97
Self-citationTreaba, C. A., Granberg, T., Sormani, M. P., Herranz, E., Ouellette, R., Louapre, C., Sloane, J. A., Kinkel, R. P., & Mainero, C. (2019) · Radiology · doi:10.1148/radiol.2019181719 · Cited by 93
Self-citationMultiple Sclerosis Phenotypes as a Continuum
Vollmer, T. L., Nair, K. V., Williams, I. M., & Álvarez, E. (2021) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000001045 · Cited by 100
Amato, M. P., & Portaccio, E. (2015) · CNS Drugs · doi:10.1007/s40263-015-0238-y · Cited by 92
Sørensen, P. S., Sellebjerg, F. T., Hartung, H.-P., Montalbán, X., Comi, G., & Tintoré, M. (2020) · Brain · doi:10.1093/brain/awaa145 · Cited by 99
Self-citationMesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical Studies
Gugliandolo, A., Bramanti, P., & Mazzon, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228662 · Cited by 94
Montalbán, X., Vermersch, P., Arnold, D. L., Bar‐Or, A., Cree, B., Cross, A. H., Havrdová, E., Kappos, L., Stüve, O., Wiendl, H., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00328-4 · Cited by 96
Self-citationAgah, E., Zardoui, A., Saghazadeh, A., Ahmadi, M., Tafakhori, A., & Rezaei, N. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190252 · Cited by 91
Piket, E., Zheleznyakova, G. Y., Kular, L., & Jagodic, M. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.04.002 · Cited by 79
Shift of multiple sclerosis onset towards older age
Prosperini, L., Lucchini, M., Ruggieri, S., Tortorella, C., Haggiag, S., Massimiliano Mirabella, A., Pozzilli, C., & Gasperini, C. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-329049 · Cited by 90
Self-citationThe relationship of age with the clinical phenotype in multiple sclerosis
Scalfari, A., Lederer, C., Däumer, M., Nicholas, R. S., Ebers, G. C., & Muraro, P. A. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516630396 · Cited by 92
The tension between early diagnosis and misdiagnosis of multiple sclerosis
Solomon, A. J., & Corboy, J. R. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.106 · Cited by 89
COVID-19 in multiple sclerosis patients and risk factors for severe infection
Chaudhry, F., Bulka, H., Rathnam, A., Said, O. M., Lin, J., Lorigan, H., Bernitsas, E., Rube, J., Korzeniewski, S. J., Memon, A. B., et al. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.117147 · Cited by 88
Sex and Gender Differences in Neurodegenerative Diseases: Challenges for Therapeutic Opportunities
Bianco, A., Antonacci, Y., & Liguori, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076354 · Cited by 90
Hecker, M., Fitzner, B., Wendt, M., Lorenz, P., Flechtner, K., Steinbeck, F., Schröder, I., Thiesen, H., & Zettl, U. K. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.051664 · Cited by 90
Golan, D., Doniger, G. M., Wissemann, K., Zarif, M., Bumstead, B., Buhse, M., Fafard, L., Lavi, I., Wilken, J. A., & Gudesblatt, M. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517695470 · Cited by 93
van Olst, L., Rodriguez-Mogeda, C., Picon, C., Kiljan, S., James, R. E., Kamermans, A., van der Pol, S. M. A., Knoop, L., Michailidou, I., Drost, E., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02293-4 · Cited by 87
Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab
de Flon, P., Gunnarsson, M., Laurell, K., Söderström, L., Birgander, R., Lindqvist, T., Krauss, W., Dring, A. M., Bergman, J., Sundström, P., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002832 · Cited by 87
Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis
Li, Z., Richards, S., Surks, H. K., Jacobs, A., & Panzara, M. A. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13208 · Cited by 87
Neurofilaments in progressive multiple sclerosis: a systematic review
Williams, T. E., Zetterberg, H., & Chataway, J. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09917-x · Cited by 87
Toward Precision Phenotyping of Multiple Sclerosis
Pitt, D., Lo, C. H., Gauthier, S. A., Hickman, R. A., Longbrake, E. E., Airas, L. M., Mao‐Draayer, Y., Riley, C., Jager, P. L. D., Wesley, S., et al. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200025 · Cited by 87
Self-citationZurawski, J. D., Lassmann, H., & Bakshi, R. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.4237 · Cited by 88
Progressive Multiple Sclerosis Is Associated with Faster and Specific Retinal Layer Atrophy
Sotirchos, E. S., Caldito, N. G., Filippatou, A. G., Fitzgerald, K. C., Murphy, O. C., Lambe, J., Nguyen, J. V., Button, J., Ogbuokiri, E., Crainiceanu, C. M., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25738 · Cited by 88
Self-citationA New Advanced MRI Biomarker for Remyelinated Lesions in Multiple Sclerosis
Rahmanzadeh, R., Galbusera, R., Lu, P., Bahn, E., Weigel, M., Baraković, M., Franz, J., Nguyen, T. D., Spincemaille, P., Schiavi, S., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26441 · Cited by 87
Self-citationHigh-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis
Thouvenot, É., Laplaud, D. A., Lebrun‐Frénay, C., Derache, N., Page, E. L., Maillart, É., Tilikete, C., Castelnovo, G., Casez, O., Coustans, M., et al. (2025) · JAMA · doi:10.1001/jama.2025.1604 · Cited by 95
Teriflunomide for multiple sclerosis
He, D., Zhang, C., Zhao, X., Zhang, Y., Dai, Q., Li, Y., & Chu, L. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009882.pub3 · Cited by 86
Brindisi, M., Maramai, S., Gemma, S., Brogi, S., Grillo, A., Di Cesare Mannelli, L., Gabellieri, E., Lamponi, S., Saponara, S., Gorelli, B., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01812 · Cited by 86
Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis
Shirani, A., Okuda, D. T., & Stüve, O. (2016) · Neurotherapeutics · doi:10.1007/s13311-015-0409-z · Cited by 87
Self-citationThe role of regulatory T cells in nervous system pathologies
Duffy, S. S., Keating, B. A., Perera, C. J., & Moalem‐Taylor, G. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24073 · Cited by 88
Stem Cell Therapy for Multiple Sclerosis
Genc, B., Bozan, H. R., Genç, Ş., & Genç, K. (2018) · Advances in experimental medicine and biology · doi:10.1007/5584_2018_247 · Cited by 88
Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
Boffa, G., Massacesi, L., Inglese, M., Mariottini, A., Capobianco, M. A. N., Moiola, L., Amato, M. P., Cottone, S., Gualandi, F., Gobbi, M. D., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011461 · Cited by 90
Self-citationPrinsen, H., de Graaf, R. A., Mason, G. F., Pelletier, D., & Juchem, C. (2016) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25356 · Cited by 84
Cytokine Signaling in Multiple Sclerosis and Its Therapeutic Applications
Palle, P., Monaghan, K. L., Milne, S. M., & Wan, E. C. K. (2017) · Medical Sciences · doi:10.3390/medsci5040023 · Cited by 91
An Overview of the History, Pathophysiology, and Pharmacological Interventions of Multiple Sclerosis
Dighriri, I. M., Aldalbahi, A. A., Albeladi, F. I., Tahiri, A. A., Kinani, E. M., Almohsen, R. A., Alamoudi, N. H., Alanazi, A. I., Alkhamshi, S. J., Althomali, N. A., et al. (2023) · Cureus · doi:10.7759/cureus.33242 · Cited by 93
Cho, J. J., Stewart, J. M., Drashansky, T. T., Brusko, M., Zuniga, A. N., Lorentsen, K. J., Keselowsky, B. G., & Avram, D. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.07.029 · Cited by 84
Ziemssen, T., Kern, R., & Thomas, K. (2016) · BMC Neurology · doi:10.1186/s12883-016-0639-7 · Cited by 83
Gross, H. J., & Watson, C. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s132079 · Cited by 90
Aggressive multiple sclerosis (1): Towards a definition of the phenotype
Iacobaeus, E., Arrambide, G., Amato, M. P., Derfuss, T., Vukusic, S., Hemmer, B., Tintoré, M., Brundin, L., for the 2018 ECTRIMS Focused Workshop Group, Berger, J. R., et al. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520925369 · Cited by 82
Self-citationVidal‐Jordana, Á., & Montalbán, X. (2017) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2016.12.001 · Cited by 82
Risk of secondary progressive multiple sclerosis: A longitudinal study
Fambiatos, A., Jokubaitis, V., Horáková, D., Havrdová, E., Trojano, M., Prat, A., Girard, M., Duquette, P., Lugaresi, A., Izquierdo, G., et al. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458519868990 · Cited by 81
Harris, C., Tang, Y., Birnbaum, E., Cherian, C., Mendhe, D., & Chen, M. H. (2024) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acae016 · Cited by 84
Campbell, J. L., Langdon, D. W., Cercignani, M., & Rashid, W. (2016) · Neural Plasticity · doi:10.1155/2016/4292585 · Cited by 88
Rajan, T. S., Giacoppo, S., Diomede, F., Bramanti, P., Trubiani, O., & Mazzon, E. (2017) · International Journal of Immunopathology and Pharmacology · doi:10.1177/0394632017722332 · Cited by 80
Zecca, C., Riccitelli, G. C., Disanto, G., Singh, A., Digesu, G. A., Panicari, L., Puccini, F., Mattioli, M., Tubaro, A., & Gobbi, C. (2016) · European Journal of Neurology · doi:10.1111/ene.13010 · Cited by 80
Flórez‐Grau, G., Zubizarreta, I., Cabezón, R., Villoslada, P., & Benítez‐Ribas, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01169 · Cited by 80
Tettey, P., Simpson, S., Taylor, B. V., Ponsonby, A., Lucas, R. M., Dwyer, T., Kostner, K., AUSLONG investigators group, & van der Mei, I. A. F. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-315037 · Cited by 79
Metze, C., Winkelmann, A., Loebermann, M., Hecker, M., Schweiger, B., Reisinger, E. C., & Zettl, U. K. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13034 · Cited by 79
Extracellular Vesicles in Neuroinflammation
Marostica, G., Gelibter, S., Gironi, M., Nigro, A., & Furlan, R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.623039 · Cited by 80
Lopez, J. A., Denkova, M., Ramanathan, S., Dale, R. C., & Brilot, F. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1316 · Cited by 79
Claflin, S. B., Broadley, S., & Taylor, B. V. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2018.01150 · Cited by 78
Gil‐Perotín, S., Castillo-Villalba, J., Cubas-Núñez, L., Gasqué-Rubio, R., Hervás, D., Gomez-Mateu, J., Alcalá, C., Miralles, F. C. P., Gascón, F., Domínguez, J. A., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01008 · Cited by 79
Involvement of cytotoxic Eomes-expressing CD4 + T cells in secondary progressive multiple sclerosis
Raveney, B. J. E., Sato, W., Takewaki, D., Zhang, C., Kanazawa, T., Lin, Y., Okamoto, T., Araki, M., Kimura, Y., Sato, N., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2021818118 · Cited by 85
Unterrainer, M., Mahler, C. F., Vomacka, L., Lindner, S., Havla, J. B., Brendel, M., Böning, G., Ertl-Wagner, B. B., Kümpfel, T., Milenkovic, V. M., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3974-7 · Cited by 78
A systematic review of modifiable risk factors in the progression of multiple sclerosis
Hempel, S., Graham, G. D., Fu, N., Estrada, E., Chen, A. Y., Miake-Lye, I., Miles, J. N. V., Shanman, R., Shekelle, P. G., Beroes, J. M., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517690270 · Cited by 77
Disease-Modifying Treatment in Progressive Multiple Sclerosis
Ciotti, J. R., & Cross, A. H. (2018) · Current Treatment Options in Neurology · doi:10.1007/s11940-018-0496-3 · Cited by 77
Akaishi, T., Takahashi, T., Misu, T., Abe, M., Ishii, T., Fujimori, J., Aoki, M., Fujihara, K., & Nakashima, I. (2020) · Scientific Reports · doi:10.1038/s41598-020-70919-w · Cited by 80
Vitamin D in Neurological Diseases
Plantone, D., Primiano, G., Manco, C., Locci, S., Servidei, S., & Stefano, N. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010087 · Cited by 81
The Framingham cardiovascular risk score in multiple sclerosis
Moccia, M., Lanzillo, R., Palladino, R., Maniscalco, G. T., Rosa, A. D., Russo, C. V., Massarelli, M., Carotenuto, A., Postiglione, E., Caporale, O., et al. (2015) · European Journal of Neurology · doi:10.1111/ene.12720 · Cited by 77
YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis
Burman, J., Raininko, R., Blennow, K., Zetterberg, H., Axelsson, M., & Malmeström, C. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.01.013 · Cited by 81
Popp, R., Fierlbeck, A. K., Knüttel, H., König, N., Rupprecht, R., Weissert, R., & Wetter, T. C. (2016) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2016.03.004 · Cited by 85
Disanto, G., Benkert, P., Lorscheider, J., Mueller, S., Vehoff, J., Zecca, C., Ramseier, S., Achtnichts, L., Findling, O., Nedeltchev, K., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0152347 · Cited by 76
Self-citationTarlinton, R. E., Хайбуллин, Т. И., Granatov, E. V., Martynova, E. V., Rizvanov, A. A., & Khaiboullina, S. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020303 · Cited by 76
The CD40–CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Aarts, S. A. B. M., Seijkens, T. T. P., van Dorst, K. J. F., Dijkstra, C. D., Kooij, G., & Lutgens, E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01791 · Cited by 76
Martin, S., McGlasson, S. L., Hunt, D. P. J., & Overell, J. R. (2019) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-319190 · Cited by 79
Rüther, B. J., Scheld, M., Dreymueller, D., Clarner, T., Kress, E., Brandenburg, L., Swartenbroekx, T., Hoornaert, C., Ponsaerts, P., Fallier‐Becker, P., et al. (2017) · Glia · doi:10.1002/glia.23202 · Cited by 76
COHAN, S. L., Hendin, B. A., Reder, A. T., Smoot, K. E., Avila, R. L., Mendoza, J. P., & Weinstock‐Guttman, B. (2021) · CNS Drugs · doi:10.1007/s40263-021-00822-z · Cited by 77
Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis
Zecca, C., Disanto, G., Sormani, M. P., Riccitelli, G. C., Cianfoni, A., Grande, F. D., Pravatà, E., & Gobbi, C. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515599246 · Cited by 76
Self-citationOverview and diagnosis of multiple sclerosis.
Hunter, S. F. (2016) · PubMed · Cited by 75
Vermersch, P., Brieva-Ruiz, L., Fox, R. J., Paul, F., Ramio-Torrenta, L., Schwab, M., Moussy, A., Mansfield, C., Hermine, O., Maciejowski, M., et al. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001148 · Cited by 74
Self-citationOntaneda, D., Tallantyre, E. C., Raza, P. C., Planchon, S. M., Nakamura, K., Miller, D. M., Hersh, C. M., Craner, M., Bale, C., Chaudhry, B. Z., et al. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106009 · Cited by 76
Self-citationPromising Nanotechnology Approaches in Treatment of Autoimmune Diseases of Central Nervous System
Chountoulesi, M., & Demetzos, C. (2020) · Brain Sciences · doi:10.3390/brainsci10060338 · Cited by 76
Role of artificial intelligence in MS clinical practice
Bonacchi, R., Filippi, M., & Rocca, M. A. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103065 · Cited by 76
Classification of Multiple Sclerosis Clinical Profiles via Graph Convolutional Neural Networks
Marzullo, A., Kocevar, G., Stamile, C., Durand‐Dubief, F., Terracina, G., Calimeri, F., & Sappey‐Marinier, D. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00594 · Cited by 73
1 H-NMR analysis provides a metabolomic profile of patients with multiple sclerosis
Cocco, E. E., Murgia, F., Lorefice, L., Barberini, L., Poddighe, S., Frau, J., Fenu, G., Coghe, G., Murru, M. R., Murru, R., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000185 · Cited by 73
Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study
Prosperini, L., Mancinelli, C. R., Solaro, C. M., Nociti, V., Haggiag, S., Cordioli, C., Giglio, L. D., Rossi, N. D., Galgani, S., Rasia, S., et al. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00847-0 · Cited by 72
Association of Spectral-Domain OCT With Long-term Disability Worsening in Multiple Sclerosis
Lambe, J., Fitzgerald, K. C., Murphy, O. C., Filippatou, A. G., Sotirchos, E. S., Kalaitzidis, G., Vasileiou, E. S., Pellegrini, N., Ogbuokiri, E., Toliver, B., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011788 · Cited by 76
Self-citationQuality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy
Young, C. A., Mills, R. J., Rog, D. J., Sharrack, B., Majeed, T., Constantinescu, C. S., Kalra, S., Harrower, T., Santander, H., Courtald, G., et al. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.117437 · Cited by 71
Fox, E., Hough, A. D., Creanor, S., Gear, M., & Freeman, J. A. (2016) · Physical Therapy · doi:10.2522/ptj.20150166 · Cited by 71
Bisecco, A., Nardo, F. D., Docimo, R., Caiazzo, G., d’Ambrosio, A., Bonavita, S., Capuano, R., Sinisi, L., Cirillo, M., Esposito, F., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517730932 · Cited by 72
Airas, L. M., Nylund, M., & Rissanen, E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00181 · Cited by 78
Diagnosis and Management of Progressive Multiple Sclerosis
Macaron, G., & Ontaneda, D. (2019) · Biomedicines · doi:10.3390/biomedicines7030056 · Cited by 70
Impact of natural menopause on multiple sclerosis: a multicentre study
Baroncini, D., Annovazzi, P. O. L., Rossi, N. D., Mallucci, G., Clerici, V. T., Tonietti, S., Mantero, V., Ferrò, M. T., Messina, M., Barcella, V., et al. (2019) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-320587 · Cited by 70
Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective
Filippi, M., Preziosa, P., Barkhof, F., Chard, D., Stefano, N. D., Fox, R. J., Gasperini, C., Kappos, L., Montalbán, X., Moraal, B., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.4689 · Cited by 73
Self-citation
Metadata
- Authors
- Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., Bebo, B., Calabresi, P. A., Clanet, M., Comi, G., Fox, R. J., Freedman, M. S., Goodman, A. D., Inglese, M., Kappos, L., Kieseier, B. C., Lincoln, J. A., Lubetzki, C., Miller, A. E., Montalban, X., O'Connor, P. W., Petkau, J., Pozzilli, C., Rudick, R. A., Sormani, M. P., Stüve, O., Waubant, E., & Polman, C. H.
- Affiliations
- Cleveland Clinic (US)
- From the Corinne Goldsmith Dickenson Center for Multiple Sclerosis (F.D.L., A.E.M.), Icahn School of Medicine at Mount Sinai, New York, NY; Scientific and Clinical Review Associates, LLC (S.C.R.), Salisbury, CT; The Mellen Center for MS Treatment and Research (J.A.C., R.J.F., R.A.R.), Cleveland Clinic, OH; the Department of Biostatistics (G.R.C.), University of Alabama at Birmingham; the Danish Multiple Sclerosis Center (P.S.S.), Department of Neurology, Copenhagen University Hospital Rigshospitalet...
- Corresponding author
- Lublin, Fred D.
- ORCID
- Lublin, Fred D.
- Reingold, Stephen C.
- Cohen, Jeffrey A.
- Cutter, Gary R.
- Sørensen, Per Soelberg
- Thompson, Alan J.
- Wolinsky, Jerry S.
- Balcer, Laura J.
- Banwell, Brenda
- Barkhof, Frederik
- Bebo, Bruce
- Calabresi, Peter A.
- Comi, Giancarlo
- Fox, Robert J.
- Goodman, Andrew D.
- Inglese, Matilde
- Kappos, Ludwig
- Lincoln, John A.
- Lubetzki, Catherine
- Miller, Aaron E.
- O'Connor, Paul W.
- Pozzilli, Carlo
- Rudick, Richard A.
- Sormani, Maria Pia
- Stüve, Olaf
- Waubant, Emmanuelle
- Polman, Chris H.
- Venue
- Neurology
- Published
- 2014-07-15
- Volume
- 83
- Issue
- 3
- Pages
- 278-286
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC4117366
- OpenAlex
- W2105206040
- Cited by
- 3,177
- References
- 32
- Citations by year
- 2026: 229 · 2025: 266 · 2024: 335 · 2023: 308 · 2022: 333 · 2021: 333 · 2020: 298 · 2019: 274 · 2018: 232 · 2017: 236 · 2016: 193 · 2015: 105 · 2014: 27
- FWCI
- 139.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Neurology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Multiple Sclerosis Society
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Celgene
- F. Hoffmann-La Roche
- Cleveland Clinic
- Novartis Pharmaceuticals Corporation
- University of Alabama at Birmingham
- European Committee for Treatment and Research in Multiple Sclerosis
- Wellcome Trust
- Ironwood Pharmaceuticals, Incorporated
- University of Alabama
- Myelin Repair Foundation
- University of Texas Health Science Center at Houston
- GW Pharmaceuticals
- Acorda Therapeutics
- Prothena
- Glenmark Pharmaceuticals
- National Institute for Health and Care Research
- Multiple Sclerosis Society
- University of Cambridge
- European Commission
- Bayer HealthCare
- Wolfson Foundation
- National Research Foundation
- Eisai
- Multiple Sclerosis International Federation
- Schweizerische Multiple Sklerose Gesellschaft
- Sun Pharma
- Serono Symposia International Foundation
- Grifols
- National Institutes of Health
- Genentech
- EMD Serono
- Bayer Canada
- Sanofi Genzyme
- Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council of Canada
- Medical Research Council
- National Heart, Lung, and Blood Institute
- National Institute of Neurological Disorders and Stroke
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Keywords
- multiple sclerosis, clinical course, disease phenotypes, clinical trial design, relapse rate, disease activity, disease progression, MRI findings, biomarkers
- MeSH terms
- Clinical Trials as Topic, Humans, Multiple Sclerosis, Societies, Medical, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
